The University of Chicago Header Logo

Connection

Richard Whitley to Herpes Zoster

Back to Details
This is a "connection" page, showing publications Richard Whitley has written about Herpes Zoster.
Richard Whitley
Connection Strength
6.598
Herpes Zoster
  1. Editorial commentary: Waning efficacy of the herpes zoster vaccine. Clin Infect Dis. 2015 Mar 15; 60(6):910-1.
    View in: PubMed
    Score: 0.490
  2. Management of herpes zoster and post-herpetic neuralgia now and in the future. J Clin Virol. 2010 May; 48 Suppl 1:S20-8.
    View in: PubMed
    Score: 0.357
  3. A 70-year-old woman with shingles: review of herpes zoster. JAMA. 2009 Jul 01; 302(1):73-80.
    View in: PubMed
    Score: 0.335
  4. Herpes zoster in the age of focused immunosuppressive therapy. JAMA. 2009 Feb 18; 301(7):774-5.
    View in: PubMed
    Score: 0.329
  5. Diagnosis and assessment of pain associated with herpes zoster and postherpetic neuralgia. J Pain. 2008 Jan; 9(1 Suppl 1):S37-44.
    View in: PubMed
    Score: 0.304
  6. Varicella zoster virus: natural history and current therapies of varicella and herpes zoster. Herpes. 2007 Sep; 14 Suppl 2:25-9.
    View in: PubMed
    Score: 0.297
  7. Varicella-zoster vaccine for the prevention of herpes zoster. N Engl J Med. 2007 Mar 29; 356(13):1338-43.
    View in: PubMed
    Score: 0.288
  8. Recommendations for the management of herpes zoster. Clin Infect Dis. 2007 Jan 01; 44 Suppl 1:S1-26.
    View in: PubMed
    Score: 0.283
  9. Changing dynamics of varicella-zoster virus infections in the 21st century: the impact of vaccination. J Infect Dis. 2005 Jun 15; 191(12):1999-2001.
    View in: PubMed
    Score: 0.253
  10. Clinical practice. Herpes zoster. N Engl J Med. 2002 Aug 01; 347(5):340-6.
    View in: PubMed
    Score: 0.209
  11. Clinical applications for change-point analysis of herpes zoster pain. J Pain Symptom Manage. 2002 Jun; 23(6):510-6.
    View in: PubMed
    Score: 0.206
  12. Phase specific analysis of herpes zoster associated pain data: a new statistical approach. Stat Med. 2001 Aug 30; 20(16):2429-39.
    View in: PubMed
    Score: 0.196
  13. Herpes zoster: focus on treatment in older adults. Antiviral Res. 1999 Dec 31; 44(3):145-54.
    View in: PubMed
    Score: 0.174
  14. A mixed model for factors predictive of pain in AIDS patients with herpes zoster. J Pain Symptom Manage. 1999 Jun; 17(6):410-7.
    View in: PubMed
    Score: 0.168
  15. Herpes zoster: risk categories for persistent pain. J Infect Dis. 1999 Jan; 179(1):9-15.
    View in: PubMed
    Score: 0.163
  16. Therapeutic approaches to the management of herpes zoster. Adv Exp Med Biol. 1999; 458:159-65.
    View in: PubMed
    Score: 0.163
  17. Approaches to the treatment of varicella-zoster virus infections. Contrib Microbiol. 1999; 3:158-72.
    View in: PubMed
    Score: 0.163
  18. The identification of risk factors associated with persistent pain following herpes zoster. J Infect Dis. 1998 Nov; 178 Suppl 1:S71-5.
    View in: PubMed
    Score: 0.161
  19. Sorivudine versus acyclovir for treatment of dermatomal herpes zoster in human immunodeficiency virus-infected patients: results from a randomized, controlled clinical trial. Collaborative Antiviral Study Group/AIDS Clinical Trials Group, Herpes Zoster Study Group. Antimicrob Agents Chemother. 1998 May; 42(5):1139-45.
    View in: PubMed
    Score: 0.155
  20. Assessment of pain in herpes zoster: lessons learned from antiviral trials. Antiviral Res. 1997 Jan; 33(2):73-85.
    View in: PubMed
    Score: 0.142
  21. Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Ann Intern Med. 1996 Sep 01; 125(5):376-83.
    View in: PubMed
    Score: 0.138
  22. Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials. Clin Infect Dis. 1996 Feb; 22(2):341-7.
    View in: PubMed
    Score: 0.133
  23. Unique clinical trial design: combination acyclovir plus prednisone therapy of localized zoster in the normal host. Antiviral Res. 1996 Jan; 29(1):67-8.
    View in: PubMed
    Score: 0.132
  24. Sorivudine: a promising drug for the treatment of varicella-zoster virus infection. Neurology. 1995 Dec; 45(12 Suppl 8):S73-5.
    View in: PubMed
    Score: 0.131
  25. Herpes zoster in patients with human immunodeficiency virus infection--an ever-expanding spectrum of disease. Clin Infect Dis. 1995 Oct; 21(4):989-90.
    View in: PubMed
    Score: 0.130
  26. Therapeutic approaches to varicella-zoster virus infections. J Infect Dis. 1992 Aug; 166 Suppl 1:S51-7.
    View in: PubMed
    Score: 0.104
  27. Disseminated herpes zoster in the immunocompromised host: a comparative trial of acyclovir and vidarabine. The NIAID Collaborative Antiviral Study Group. J Infect Dis. 1992 Mar; 165(3):450-5.
    View in: PubMed
    Score: 0.101
  28. Natural history and treatment of varicella-zoster in high-risk populations. J Hosp Infect. 1991 Jun; 18 Suppl A:317-29.
    View in: PubMed
    Score: 0.096
  29. Incomplete financial disclosures in an editorial, clinical crossroads, and reply letter related to herpes zoster. JAMA. 2010 Feb 24; 303(8):733-4.
    View in: PubMed
    Score: 0.088
  30. Varicella-zoster virus infections: chronic disease in the immunocompromised host: evidence for persistent excretion of virus. Pediatr Infect Dis J. 1989 Sep; 8(9):584-5.
    View in: PubMed
    Score: 0.085
  31. CNS diseases associated with varicella zoster virus and herpes simplex virus infection. Pathogenesis and current therapy. Neurol Clin. 1986 Feb; 4(1):265-83.
    View in: PubMed
    Score: 0.067
  32. Herpesvirus infections of pregnancy. Part II: Herpes simplex virus and varicella-zoster virus infections. N Engl J Med. 1985 Nov 21; 313(21):1327-30.
    View in: PubMed
    Score: 0.066
  33. Early vidarabine therapy to control the complications of herpes zoster in immunosuppressed patients. N Engl J Med. 1982 Oct 14; 307(16):971-5.
    View in: PubMed
    Score: 0.053
  34. Antiviral agents: clinical status report. Hosp Pract (Off Ed). 1981 Jul; 16(7):109-21.
    View in: PubMed
    Score: 0.048
  35. Distribution of adenine arabinoside and interferon. JAMA. 1979 Sep 21; 242(12):1259-60.
    View in: PubMed
    Score: 0.043
  36. NIH conference. Herpes zoster-varicella infections in immunosuppressed patients. Ann Intern Med. 1978 Sep; 89(3):375-88.
    View in: PubMed
    Score: 0.040
  37. Advances in the management of herpesvirus infections. Introduction. Semin Dermatol. 1996 Jun; 15(2 Suppl 1):1-3.
    View in: PubMed
    Score: 0.034
  38. Adenine arabinoside therapy of herpes zoster in the immunosuppressed. NIAID collaborative antiviral study. N Engl J Med. 1976 May 27; 294(22):1193-9.
    View in: PubMed
    Score: 0.034
  39. Acyclovir: a decade later. N Engl J Med. 1992 Sep 10; 327(11):782-9.
    View in: PubMed
    Score: 0.026
  40. Acyclovir: the past ten years. Adv Exp Med Biol. 1990; 278:243-53.
    View in: PubMed
    Score: 0.022
  41. Analysis of immune function in herpes zoster patients: demonstration and characterization of suppressor cells. J Immunol. 1987 Feb 15; 138(4):1229-33.
    View in: PubMed
    Score: 0.018
  42. T-cell imbalances and NK activity in varicella-zoster virus infections. Viral Immunol. 1987; 1(2):145-52.
    View in: PubMed
    Score: 0.018
  43. Demonstration of NK cell-mediated lysis of varicella-zoster virus (VZV)-infected cells: characterization of the effector cells. J Immunol. 1986 Jun 01; 136(11):4243-8.
    View in: PubMed
    Score: 0.017
  44. Herpesvirus infections in the immunocompromised host: diagnosis and management. Adv Exp Med Biol. 1986; 202:95-118.
    View in: PubMed
    Score: 0.017
  45. High-pressure liquid chromatographic methods for determining arabinosyladenine-5'-monophosphate, arabinosyladenine, and arabinosylhypoxanthine in plasma and urine. Antimicrob Agents Chemother. 1985 Aug; 28(2):265-73.
    View in: PubMed
    Score: 0.016
  46. Therapy for human herpesvirus infections. A perspective. Ala J Med Sci. 1985 Apr; 22(2):193-207.
    View in: PubMed
    Score: 0.016
  47. Treatment of human herpesvirus infections with special reference to encephalitis. J Antimicrob Chemother. 1984 Aug; 14 Suppl A:57-74.
    View in: PubMed
    Score: 0.015
  48. Herpes zoster in early infancy. Am J Dis Child. 1980 Jun; 134(6):618-9.
    View in: PubMed
    Score: 0.011
  49. Plasma levels and urinary excretion of vidarabine after repeated dosing. Clin Pharmacol Ther. 1980 May; 27(5):690-6.
    View in: PubMed
    Score: 0.011
  50. Serum antibody levels as risk factors in the dissemination of herpes zoster. Arch Intern Med. 1979 Dec; 139(12):1341-5.
    View in: PubMed
    Score: 0.011
  51. Developmental aspects of adenine arabinoside for parenteral therapy of human herpesvirus infections. Adv Ophthalmol. 1979; 38:288-96.
    View in: PubMed
    Score: 0.010
  52. Current status of antiviral chemotherapy. South Med J. 1978 Sep; 71(9):1134-40.
    View in: PubMed
    Score: 0.010
  53. Treatment of infections due to Herpesvirus in humans: a critical review of the state of the art. J Infect Dis. 1976 Jun; 133 Suppl:A101-8.
    View in: PubMed
    Score: 0.009
  54. Adenine arabinoside for therapy of herpes zoster in immunosuppressed patients: preliminary results of a collaborative study. J Infect Dis. 1976 Jun; 133 Suppl:A184-91.
    View in: PubMed
    Score: 0.009
  55. Individual NK cell clones lyse both tumor cell targets and herpes simplex virus-infected fibroblasts in the absence of interferon. Viral Immunol. 1990; 3(3):217-24.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.